159 related articles for article (PubMed ID: 30866035)
1. Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer.
Considine B; Petrylak DP
Oncology (Williston Park); 2019 Mar; 33(3):113-8. PubMed ID: 30866035
[TBL] [Abstract][Full Text] [Related]
2. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
3. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
4. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
5. Advancing therapies in metastatic castration-resistant prostate cancer.
Baciarello G; Gizzi M; Fizazi K
Expert Opin Pharmacother; 2018 Nov; 19(16):1797-1804. PubMed ID: 30311804
[TBL] [Abstract][Full Text] [Related]
6. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
Considine B; Petrylak DP
Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
[TBL] [Abstract][Full Text] [Related]
7. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
Fujimoto N
Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
[TBL] [Abstract][Full Text] [Related]
8. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
10. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer.
Thelen P; Wuttke W; Seidlová-Wuttke D
J Steroid Biochem Mol Biol; 2014 Jan; 139():290-3. PubMed ID: 23872207
[TBL] [Abstract][Full Text] [Related]
11. Progress in the mechanism and drug development of castration-resistant prostate cancer.
Zuo M; Xu X; Li T; Ge R; Li Z
Future Med Chem; 2016 May; 8(7):765-88. PubMed ID: 27149562
[TBL] [Abstract][Full Text] [Related]
12. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.
Roviello G; Sigala S; Sandhu S; Bonetta A; Cappelletti MR; Zanotti L; Bottini A; Sternberg CN; Fox SB; Generali D
Eur J Cancer; 2016 Jul; 61():111-21. PubMed ID: 27162152
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.
Mayer MJ; Klotz LH; Venkateswaran V
J Urol; 2017 Apr; 197(4):1068-1075. PubMed ID: 27984108
[TBL] [Abstract][Full Text] [Related]
14. Drug therapies for metastatic castration-resistant prostate cancer.
El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
[TBL] [Abstract][Full Text] [Related]
15. Targeting molecular resistance in castration-resistant prostate cancer.
Chandrasekar T; Yang JC; Gao AC; Evans CP
BMC Med; 2015 Sep; 13():206. PubMed ID: 26329698
[TBL] [Abstract][Full Text] [Related]
16. [New therapies in metastatic castration resistant prostate cancer].
Thibault C; Massard C
Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
[TBL] [Abstract][Full Text] [Related]
17. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
Shiota M; Eto M
Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
[TBL] [Abstract][Full Text] [Related]
18. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
Basset V; Flamand V; Crouzet S; Ploussard G
Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
[TBL] [Abstract][Full Text] [Related]
19. Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC.
Giacinti S; Poti G; Roberto M; Macrini S; Bassanelli M; DI Pietro F; Aschelter AM; Ceribelli A; Ruggeri EM; Marchetti P
Anticancer Res; 2018 Nov; 38(11):6029-6039. PubMed ID: 30396917
[TBL] [Abstract][Full Text] [Related]
20. Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
Chopra S; Rashid P
Aust Fam Physician; 2015 May; 44(5):302-5. PubMed ID: 26042402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
